









Markets
/
Stocks
/
nasdaq-grce
/

Grace Therapeutics, Inc

GRCE

3.600USD

+0.120+3.45%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

50.86MMarket Cap

LossP/E TTM



Grace Therapeutics, Inc

3.600

+0.120+3.45%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Grace Therapeutics, Inc

Currency: USD Updated: 2026-02-06

Key Insights

Grace Therapeutics, Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 128 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.67.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Grace Therapeutics, Inc's Score

Industry at a Glance

Industry Ranking

128 / 392

Overall Ranking

266 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Grace Therapeutics, Inc Highlights

StrengthsRisks

Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.

Undervalued

The company’s latest PE is -6.72, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 3.72M shares, increasing 0.34% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 423.98K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.42.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.667

Target Price

+235.25%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Grace Therapeutics, Inc is 5.63, ranking 342 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.63

Change



Financials

4.15

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.67

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.66

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.79

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

6.87

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Grace Therapeutics, Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Grace Therapeutics, Inc is 7.63, ranking 96 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -6.72, which is -95.71% below the recent high of -0.29 and -6.39% above the recent low of -7.15.

Score

Industry at a Glance

Previous score

7.63

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 128/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Grace Therapeutics, Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 12.00, with a high of 12.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

11.667

Target Price

+235.25%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Grace Therapeutics, Inc

GRCE

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Grace Therapeutics, Inc is 6.79, ranking 169 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.89 and the support level at 3.35, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.43

Change

0.36

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.053

Neutral

RSI(14)

50.008

Neutral

STOCH(KDJ)(9,3,3)

31.168

Neutral

ATR(14)

0.217

Low Volatility

CCI(14)

-66.385

Neutral

Williams %R

62.825

Sell

TRIX(12,20)

0.165

Sell

StochRSI(14)

42.566

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

3.644

Sell

MA10

3.646

Sell

MA20

3.654

Sell

MA50

3.489

Buy

MA100

3.286

Buy

MA200

3.145

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Grace Therapeutics, Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 24.07%, representing a quarter-over-quarter decrease of 8.89%. The largest institutional shareholder is The Vanguard, holding a total of 423.98K shares, representing 2.74% of shares outstanding, with 8.78% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Shore Pharma LLC

1.34M

+12.40%

Nantahala Capital Management, LLC

1.18M

SS Pharma LLC

1.08M

+15.81%

Rajitha Grace 2018 Irrevocable Trust

781.59K

AIGH Capital Management, LLC.

670.36K

-20.20%

BofA Global Research (US)

494.70K

Kottayil (George)

494.70K

Kavuru (Vimal)

426.32K

The Vanguard Group, Inc.

Star Investors

409.10K

Adar1 Capital Management LLC

350.45K

+98.41%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Grace Therapeutics, Inc is 4.50, ranking 84 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.75. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.